Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    C3441021
Previous Study | Return to List | Next Study

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03395197
Recruitment Status : Recruiting
First Posted : January 10, 2018
Last Update Posted : July 16, 2019
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.

Condition or disease Intervention/treatment Phase
mCRPC Drug: Talazoparib with enzalutamide Drug: Placebo with enzalutamide Phase 3

Detailed Description:
Part 1 is an open-label, non-randomized, safety and PK run-in study designed to confirm the starting dose of talazoparib in combination with enzalutamide through assessment of target safety events and PK at select sites. Part 2 is a randomized, double-blind, placebo-controlled, multinational study comparing talazoparib plus enzalutamide vs. placebo plus enzalutamide in patients with mCRPC.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 872 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: To assess radiographic PFS in men with mCRPC (with no systemic treatments initiated after documentation of mCRCP) treated with talazoparib and enzalutamide vs. placebo plus enzalutamide
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double-blind.
Primary Purpose: Treatment
Official Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Actual Study Start Date : December 18, 2017
Estimated Primary Completion Date : September 14, 2022
Estimated Study Completion Date : November 25, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Combination arm
Talazoparib plus enzalutamide
Drug: Talazoparib with enzalutamide
Talazoparib 0.5 mg/day plus enzalutamide 160mg/day

Active Comparator: Monotherapy arm
Ezalutamide plus placebo
Drug: Placebo with enzalutamide
Placebo plus enzalutamide 160 mg/day




Primary Outcome Measures :
  1. Confirm the dose of Talazoparib (part 1) [ Time Frame: Day 1 up to 28 days ]
    determined based on the safety profile

  2. Radiographic PFS (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: randomization up to 25 months ]
    time from the date of randomization to first objective evidence of radiographic progression by blinded independent review, or death (occurring within 168 days of treatment discontinuation), whichever occurs first


Secondary Outcome Measures :
  1. Overall survival (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: randomization up to 47 months ]
    time from randomization to death from any cause

  2. Objective response in measurable soft tissue disease (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: baseline up to 6 months ]
    proportion of patients with measurable soft tissue disease at baseline with objective response per RECIST 1.1

  3. Duration of soft tissue response (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: baseline up to 25 months ]
    duration of responses in patients with measurable soft tissue disease at baseline per RECIST 1.1

  4. PSA response (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: baseline up to 25 months ]
    proportion of patients with PSA response grater than or equal to 50%

  5. Time to PSA progression (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: baseline up to 25 months ]
    time from baseline to PSA progression

  6. Time to initiation of cytotoxic chemotherapy (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: randomization up to 47 months ]
    time from randomization to initiation of cytotoxic chemotherapy

  7. Time to initiation of antineoplastic therapy (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: randomization up to 47 months ]
    time from randomization to initiation of antineoplastic treatment

  8. Time to first symptomatic skeletal event (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: randomization up to 47 months ]
    time from randomization to first symptomatic skeletal event (symptomatic fractures, spinal cord compression, surgery or radiation to the bone whichever is first)

  9. PFS on next line of therapy (PFS2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: randomization up to 47 months ]
    PFS2 based on investigator assessment

  10. Opiate use for cancer pain (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: randomization up to 47 months ]
    time from randomization to opiate use for prostate cancer pain

  11. Incidence of adverse events (part 1 and 2) [ Time Frame: Day 1 up to 26 months ]
    AEs and SAEs incidence by type and severity (graded by NCI CTCAE version 4.03)

  12. Pharmacokinetic assessment of talazoparib (part 1) [ Time Frame: Week 1, 5, 9, and 13 ]
    plasma concentration of talazoparib

  13. Pharmacokinetic assessment of talazoparib (part 2) [ Time Frame: week 3, 5, 9 13, and 17 ]
    plasma concentration of talazoparib

  14. Pharmacokinetic assessment of enzalutamide (part 1) [ Time Frame: week 1, 5, 9, and 13 ]
    plasma concentration of enzalutamide

  15. Pharmacokinetic assessment of enzalutamide (part 2) [ Time Frame: week 3, 5, 9 13, and 17 ]
    plasma concentration of enzalutamide

  16. Patient-reported outcome:pain symptoms (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: baseline up to 47 months ]
    change from baseline in patient-reported pain symptoms per Brief Pain Inventory Short Form (BPI-SF)

  17. Patient-reported outcome: pain symptoms (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: baseline up to 47 months ]
    time to deterioration in patient-reported pain symptoms per Brief Pain Inventory Short Form (BPI-SF)

  18. Patient-reported outcome: cancer specific global health status/QoL, functioning, and symptoms (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: baseline up to 47 months ]
    change from baseline in patient-reported Global health status/QoL per EORTC QLQ-C30

  19. Patient-reported outcome: cancer specific global health status/QoL, functioning, and symptoms (part 2) in unselected patients and in patients harboring DDR deficiencies [ Time Frame: baseline up to 47 months ]
    time to definitive deterioration in patient-reported global health status/QoL per EORTC QLQ-C30

  20. Patient-reported outcome: general health status (part2) in unselected patients and patients harboring DDR deficiencies [ Time Frame: baseline up to 47 months ]
    change from baseline in patient-reported general health status per EQ-5D-5L

  21. Patient-reported outcome: general health status (part 2) in unselected patients and patients harboring DDR deficiencies [ Time Frame: baseline up to 47 months ]
    time to definitive deterioration in patient-reported disease-specific urinary symptoms per EORTC QLQ-PR25



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Men at least 18 years of age. For Japan, at least 20 years of age.
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Histologically or cytologically confirmed adenocarcinoma of the prostate withoutsmall cell or signet cell features

Asymptomatic or mildly symptomatic metastatic castration resistant prostate cancer (mCRPC) (score on BPI-SF Question #3 must be < 4).

For enrollment into Part 2 only (optional in Part 1): assessment of DDR mutation status

Consent to a saliva sample collection for a germline comparator unless prohibited by local regulations or ethics committee decision (optional for patients in Part 1).

Surgically or medically castrated, with serum testosterone ≤ 50 ng/dL (≤ 1.73 nmol/L) at screening.

Metastatic disease in bone documented on bone scan or in soft tissue documented on CT/MRI scan.

Progressive disease at study entry in the setting of medical or surgical castration as defined by 1 or more of the following 3 criteria:

  • Prostate specific antigen (PSA) progression defined by a minimum of 2 rising PSA values from 3 consecutive assessments with an interval of at least 7 days between assessments..
  • Soft tissue disease progression as defined by RECIST 1.1.
  • Bone disease progression defined by Prostate Cancer Working Group 3 (PCWG3) with 2 or more new metastatic bone lesions on a whole body radionuclide bone scan.

Bisphosphonate or denosumab dosage must have been stable for at least 4 weeks before Day 1 (Part 1) or randomization (Part 2) for patients receiving these therapies

Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.

Life expectancy ≥ 12 months as assessed by the investigator.

Able to swallow the study drug and have no known intolerance to study drugs or excipients.

Must agree to use a condom when having sex with a partner from the time of the first dose of study drug through 4 months after last dose of study treatment. Must also agree for female partner of childbearing potential to use an additional highly effective form of contraception from the time of the first dose of study treatment through 4 months after last dose of study treatment when having sex with a non pregnant female partner of childbearing potential.

Must agree not to donate sperm from the first dose of study drug to 4 months after the last dose of study drug.

Evidence of a personally signed and dated informed consent document (and molecular prescreening consent if appropriate) indicating that the patient [or a legally acceptable representative/legal guardian] has been informed of all pertinent aspects of the study.

Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion Criteria:

Any prior systemic cancer treatment initiated in in the non metastatic CRPC and mCRPC disease state.

Patients whose only evidence of metastasis is adenopathy below the aortic bifurcation.

Prior treatment with a PARP inhibitor, cyclophosphamide, or mitoxantrone for prostate cancer.

Prior treatment with platinum-based chemotherapy within 6 months prior to Day 1 (Part 1) or randomization (Part 2), or any history of disease progression on platinum-based therapy at any time in the past.

Treatment with cytotoxic chemotherapy, biologic therapy including sipuleucel T (other than approved bone targeting agents and GnRH agonist/antagonist therapy), or radionuclide therapy in the 28 days prior to Day 1 (Part 1) or randomization (Part 2).

Treatment with any investigational agent within 4 weeks or 5 half-lives of the drug (whichever is longer) before Day 1 (Part 1) or randomization (Part 2).

Prior treatment with opioids for pain related to either primary prostate cancer or metastasis within 28 days prior to Day 1 (Part 1) or randomization (Part 2) unless no pain related to prostate cancer has been reported in the 28 days prior to Day 1 (Part 1) or randomization (Part 2).

Current use (within 7 days prior to Day 1 (Part 1) or randomization (Part 2) or anticipated use during the study of the following medications:

  • Potential DDI with talazoparib: P gp inhibitors (amiodarone, carvedilol, clarithromycin, cobicistat, darunavir, dronedarone, erythromycin, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, telaprevir, tipranavir, verapamil, and valspodar).
  • Potential DDI with enzalutamide: strong cytochrome P450 2C8 (CYP2C8) inducers (eg, rifampin), strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifabutin and rifapentine), moderate CYP3A4 inducers (eg, bosentan, efavirenz, etravirine, modafinil and nafcillin), and substrates of CYP3A4 (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus), CYP2C9 (eg, phenytoin), or CYP2C19 (eg, S mephenytoin) with a narrow therapeutic index.

Major surgery (as defined by the investigator) within 2 weeks before Day 1 (Part 1) or randomization (Part 2).

Clinically significant cardiovascular disease

Significant renal dysfunction as defined by any of the following laboratory abnormalities:

• Renal: eGFR < 30 mL/min/1.73 m2 by the MDRD equation (available via www.mdrd.com).

Patients enrolled in Part 1 only: Moderate renal impairment (eGFR 30-59 mL/min/1.73 m2) at screening.

Significant hepatic dysfunction as defined by any of the following laboratory abnormalities on screening labs:

  • Total serum bilirubin >1.5 times the upper limit of normal (ULN) (>3 × ULN for patients with documented Gilbert syndrome or for whom indirect bilirubin concentrations suggest an extrahepatic source of elevation).
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 times ULN (>5 × ULN if liver function abnormalities are due to hepatic metastasis).
  • Albumin <2.8 g/dL

Absolute neutrophil count < 1500/µL, platelets < 100,000/µL, or hemoglobin < 9 g/dL (may not have received growth factors or blood transfusions within 14 days before obtaining the hematology values at screening).

Known or suspected brain metastasis or active leptomeningeal disease.

Symptomatic or impending spinal cord compression or cauda equina syndrome.

History of another cancer including myelodysplastic syndrome or acute myeloid leukemia, with the exception of uncomplicated nonmelanoma skin cancers, or American Joint Committee on Cancer stage 0 or stage 1 cancer that has a remote probability of recurrence in the opinion of the investigator and the sponsor

Gastrointestinal disorder affecting absorption.

Fertile male subjects who are unwilling or unable to use highly effective methods of contraception for the duration of the study and for 4 months after the last dose of investigational product.

Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees, including their family members, directly involved in the conduct of the study.

Other acute or chronic medical (concurrent disease, infection, or comorbidity) or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that interferes with ability to participate in the study, may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

History of seizure or any condition that may predispose to seizure (eg, prior cortical stroke, significant brain trauma). Also, history of loss of consciousness or transient ischemic attack within 12 months of randomization (Part 2).


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03395197


Contacts
Layout table for location contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

  Show 119 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT03395197     History of Changes
Other Study ID Numbers: C3441021
2017-003295-31 ( EudraCT Number )
TALAPRO-2 ( Other Identifier: Alias Study Number )
First Posted: January 10, 2018    Key Record Dates
Last Update Posted: July 16, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
URL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Pfizer:
mCRPC (metastatic castration-resistant prostate cancer)

Additional relevant MeSH terms:
Layout table for MeSH terms
Talazoparib
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents